Aug 28, 2024 / 12:00PM GMT
Juho Jalkanen - Faron Pharmaceuticals Oy - Chief Operating Officer
Welcome, everybody, to the H1 results webcast of Faron Pharmaceuticals. My name is Juho Jalkanen, the CEO of the company. I hope you've all had a relaxing summer charging your batteries because we have an action-packed second half coming up but before we go into that, let's have a look at what the first half looked like.
Standard disclaimer because we will be making some forward-looking statements. But what brings us all together here relapsed refractory MDS a dreadful condition, very poor survival, basically no effective treatment options, nothing. On the other hand, on the right-hand side, what can we possibly bring to the table we can extend survival. We have an excellent response rate. We can possibly truly change the treatment paradigm in this condition. But then to the actual H1 results.
I'm going to hand it over to our Chief Financial Officer, Yrjo.
Erik Ostrowski - Faron Pharmaceuticals Oy - Non-Executive Director
Hello. My name is Yrjö Wichmann. I'm the Chief
Half Year 2024 Faron Pharmaceuticals Oy Earnings Call Transcript
Aug 28, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers